The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 11, 2012
Filed:
Dec. 04, 2009
Ruihong Chen, Foster City, CA (US);
Allan E. Rubenstein, New York, NY (US);
Jin-chen Yu, Palo Alto, CA (US);
Nicolas Winssinger, Strasbourg, FR;
Sofia Barluenga, Strasbourg, FR;
Ruihong Chen, Foster City, CA (US);
Allan E. Rubenstein, New York, NY (US);
Jin-Chen Yu, Palo Alto, CA (US);
Nicolas Winssinger, Strasbourg, FR;
Sofia Barluenga, Strasbourg, FR;
Nexgenix Pharmaceuticals, LLC, New York, NY (US);
Universite de Strasbourg, Strasbourg, FR;
Abstract
The present invention provides compounds of formulae Ia, Ia', IIa, IIa′, IIIa, IIIa′, IVa, or Va and the therapeutic use thereof. The present invention also includes methods of treating NF2-deficient or NF1-deficient cells or neurodegenerative diseases with radicicol or its derivatives, such as one or more compounds of formula I, II, III, IV, V, Ia, Ia′, IIa, IIa′, IIIa, IIIa′, IVa, or Va. Furthermore, the present invention is directed to methods of inhibiting the growth of NF2-deficient or NF1-deficient tumors. The methods comprise contacting NF2-deficient or NF1-deficient tumor cells with radicicol or its derivatives, such as one or more compounds of formula I, II, III, IV, V, Ia, Ia′, IIa, IIa′, IIIa, IIIa′, IVa, or Va. The present invention is also directed to the combinational use of radicicol or its derivatives, such as one or more compounds of formula I, II, III, IV, V, Ia, Ia′, IIa, IIa′, IIIa, IIIa′, IVa, or Va with at least one additional active agent, such as one or more HSP90 inhibitors.